by Peter Ciszewski| Published on: Nov 19, 2017
Philippe Maitre, Executive Vice President, US Operations for Onxeo discusses Livatag, a nanoparticle formulation of doxorubicin (Transdrug technology) developed for the treatment of primary liver cancer.
by Peter Ciszewski| Published on: Sep 25, 2017
Philippe Maitre, Executive Vice President, US Operations for Onxeo discusses Livatag, a nanoparticle formulation of doxorubicin (Transdrug technology) developed for the treatment of primary liver cancer.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
